Table 3 Disease events prevented with the nine-valent vaccine universal vaccination in comparison with the current strategy (the quadrivalent vaccine girls-only vaccination)
From: Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
Disease event | Years since start of vaccination programme | |||
|---|---|---|---|---|
5 | 25 | 50 | 100 | |
Females | ||||
 Cervical cancer | 0 | 367 | 4623 | 22,640 |
 CIN 1 | 23 | 6961 | 34,753 | 105,431 |
 CIN 2/3 | 25 | 10,193 | 54,709 | 170,286 |
 Vaginal cancer | 0 | 0 | 13 | 88 |
 VAIN 2/3 | 0 | 0 | 0 | 0 |
 Vulvar cancer | 0 | 1 | 21 | 130 |
 Genital warts and HPV 6/11-related CIN 1 | 33 | 2438 | 6270 | 13,658 |
 Genital warts | 1411 | 61,285 | 161,443 | 358,140 |
 Anal cancer | 0 | 11 | 318 | 2619 |
Males | ||||
 Genital warts | 6101 | 208,935 | 615,645 | 1508,705 |
 Anal cancer | 0 | 28 | 748 | 5492 |